A review of available studies on Efavirenz has found no increased risk of overall birth defects among women exposed to the antiretroviral during the first trimester of pregnancy compared with exposure to other antiretroviral drugs. The results were published in the AIDS Journal and comes after the South African Government opted not to include the drug due to what specialists described a unfounded fears of birth defects.